Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

ICU - SeaStar Medical Holding Corporation... | Finranks

Home

ICU

S

SeaStar Medical Holding Corporation (ICU)

NCM – Real Time Price. Currency in USD

2.74

-0.05 (-1.79%)

At close: Mar 27, 2026, 4:00 PM EDT

2.69

-0.05 (-1.82%)

After-hours: Mar 27, 2026, 7:58 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Added top-rated children's hospitals to QUELIMMUNE™ pediatric Acute Kidney Injury (AKI) customer base Completed enrollment in FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry Exceeded 50% enrollment milestone in pivotal trial of SCD therapy in adult patients with AKI Advanced pipeline indications with initiation of cardio-renal clinical trial Webcast today at 4:30 pm Eastern Time DENVER, March 25, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months and year ended December 31, 2025, and provided business updates on key initiatives. “In 2025, we broadened our customer base of top-ranked children's hospitals, continued enrollment in the NEUTRALIZE-AKI pivotal clinical trial, and advanced our pipeline with the initiation of the cardio-renal clinical trial of our selective cytopheretic device (SCD) therapy,” said Eric Schlorff, CEO of SeaStar Medical.

SeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026

SeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026

DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2025 financial results after market close on Wednesday, March 25, 2026, and host a webcast and conference call to discuss its financial results and business progress.

SeaStar Medical to Present at the Life Sciences Investor Forum on March 11th

SeaStar Medical to Present at the Life Sciences Investor Forum on March 11th

The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.com The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.com

SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI

SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI

Completion of enrollment marks a key milestone toward satisfying FDA post-approval requirements Completion of enrollment marks a key milestone toward satisfying FDA post-approval requirements

SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)

SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)

Strong survival data extending to 90 days Real-world experience shows results consistent with clinical trial data Favorable safety profile – no device-related adverse events DENVER, Feb. 09, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today the publication of early post-approval clinical experience from the use of the QUELIMMUNE (Selective Cytopheretic Device for Pediatrics, or SCD-PED) therapy in the prestigious, peer-reviewed journal Pediatric Nephrology . The publication, co-authored by leading experts including Stuart Goldstein, Kelli Krallman, Meredith Harris, Rajit Basu, David Askenazi, Shina Menon, Matt Zinter, Steven Gorga, and H.

SeaStar Medical to Present at Upcoming Noble Capital Markets Emerging Growth Virtual Equity Conference

SeaStar Medical to Present at Upcoming Noble Capital Markets Emerging Growth Virtual Equity Conference

DENVER, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at Noble Capital Markets' Emerging Growth Virtual Equity Conference on Thursday, February 5th at 11:30 am Eastern Time.

SeaStar Medical Announces 2026 Milestones

SeaStar Medical Announces 2026 Milestones

Drive adoption of QUELIMMUNE for ultra-rare pediatric AKI, expanding revenue and doubling the customer base Advance SeaStar Medical's first-in-class SCD therapy for the adult AKI indication – a potential $4.5 billion market – through completion of enrollment of the NEUTRALIZE-AKI pivotal trial and initiation of the PMA process Progress the clinical development of the SCD therapy in patients with severe heart failure Leverage rapid pathways to commercialization of the SCD therapy through additional FDA Humanitarian Use and Breakthrough Device Designations DENVER, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today its key milestones for 2026. “Our first full year as a commercial company provided a clear demonstration that the Selective Cytopheretic Device (SCD) therapy can save lives and spare organ function, with major pediatric medical institutions, such as Cincinnati Children's Hospital, Stanford Medical Center, UCSF Benioff Children's Hospitals, and University of Michigan, adopting the therapy and reporting their findings,” said Eric Schlorff, CEO of SeaStar Medical.

Videos

No Data

There is no data to display

Press releases

SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Added top-rated children's hospitals to QUELIMMUNE™ pediatric Acute Kidney Injury (AKI) customer base Completed enrollment in FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry Exceeded 50% enrollment milestone in pivotal trial of SCD therapy in adult patients with AKI Advanced pipeline indications with initiation of cardio-renal clinical trial Webcast today at 4:30 pm Eastern Time DENVER, March 25, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months and year ended December 31, 2025, and provided business updates on key initiatives. “In 2025, we broadened our customer base of top-ranked children's hospitals, continued enrollment in the NEUTRALIZE-AKI pivotal clinical trial, and advanced our pipeline with the initiation of the cardio-renal clinical trial of our selective cytopheretic device (SCD) therapy,” said Eric Schlorff, CEO of SeaStar Medical.

SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI

SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI

Completion of enrollment marks a key milestone toward satisfying FDA post-approval requirements Completion of enrollment marks a key milestone toward satisfying FDA post-approval requirements

SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)

SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)

Strong survival data extending to 90 days Real-world experience shows results consistent with clinical trial data Favorable safety profile – no device-related adverse events DENVER, Feb. 09, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today the publication of early post-approval clinical experience from the use of the QUELIMMUNE (Selective Cytopheretic Device for Pediatrics, or SCD-PED) therapy in the prestigious, peer-reviewed journal Pediatric Nephrology . The publication, co-authored by leading experts including Stuart Goldstein, Kelli Krallman, Meredith Harris, Rajit Basu, David Askenazi, Shina Menon, Matt Zinter, Steven Gorga, and H.

SeaStar Medical Announces 2026 Milestones

SeaStar Medical Announces 2026 Milestones

Drive adoption of QUELIMMUNE for ultra-rare pediatric AKI, expanding revenue and doubling the customer base Advance SeaStar Medical's first-in-class SCD therapy for the adult AKI indication – a potential $4.5 billion market – through completion of enrollment of the NEUTRALIZE-AKI pivotal trial and initiation of the PMA process Progress the clinical development of the SCD therapy in patients with severe heart failure Leverage rapid pathways to commercialization of the SCD therapy through additional FDA Humanitarian Use and Breakthrough Device Designations DENVER, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today its key milestones for 2026. “Our first full year as a commercial company provided a clear demonstration that the Selective Cytopheretic Device (SCD) therapy can save lives and spare organ function, with major pediatric medical institutions, such as Cincinnati Children's Hospital, Stanford Medical Center, UCSF Benioff Children's Hospitals, and University of Michigan, adopting the therapy and reporting their findings,” said Eric Schlorff, CEO of SeaStar Medical.